McKesson (MCK) Q2 FY2027 Earnings Call: Q&A Summary

Q: Glen Santangelo from Barclays asked how the Precision Medicine Group and Option Care Health acquisitions fit into reporting segments, the margin impact, and the outlook for margins in Oncology & Multispecialty and Prescription Technology Solutions given upcoming biosimilar launches.

A: Brian Tyler stated that Precision Medicine Group will report under Oncology & Multispecialty, noting it complements their oncology and biopharma services. Kenny Cheung added that the acquisition is expected to be accretive, contributing $0.10 to $0.20 of adjusted EPS in fiscal '27, with $1.60 to $1.80 accretion by year 3, while Option Care Health will be an equity method investment reported in the Corporate segment.

Q: Brian Tanquilut from Jefferies asked if there is an overlay for the oncology business regarding the Option Care investment beyond incremental revenue and access.

A: Brian Tyler explained that the investment aligns with their conviction in community-based and home-based care for specialty therapies, including rare, orphan, cell, and gene therapies, viewing it as a complementary channel to their existing assets.

Q: Elizabeth Evercore asked about the sustainability of the growth in the North American Pharmaceutical segment over the long term given recent outperformance.

A: Kenny Cheung attributed the 22% operating profit growth to broad-based strength, including prescription volume, specialty products, and GLP-1s, noting that the outlook for the second half incorporates continued momentum, operational excellence, and the recently renewed CVS contract.

Q: Lisa Gill from JPMorgan asked how potential changes to 340B, such as a rebate model, might impact volume and what the company's thoughts are on the policy environment following the recent election.

A: Brian Tyler noted that while the implementation of a rebate model is uncertain, McKesson is prepared to support customers in any channel. He added that the company remains engaged with policymakers to advocate for community-based providers and does not expect a material financial impact from 340B changes.

Q: Kevin Caliendo from UBS asked what needs to happen for the North American Pharmaceutical segment to grow within the long-term plan given that recent performance has exceeded those targets.

A: Kenny Cheung reiterated confidence in their long-term targets of 13% to 16% EPS growth, driven by oncology, multi-specialty, and biopharma solutions, while Brian Tyler added that current performance reflects years of strategic investment in technology and operational execution.

Q: Allen Lutz from Bank of America asked about the relative integration complexity of Precision Medicine Group and Option Care compared to previous M&A activity.

A: Brian Tyler explained that Precision Medicine Group is highly adjacent and complementary to existing businesses, requiring thoughtful integration rather than heavy restructuring. Regarding Option Care, he noted that as a minority nonoperating partner, McKesson will rely on CD&R for day-to-day operations while providing specialty expertise.

Q: Joel Findlay from Leerink Partners asked if the Option Care deal should be viewed as an operating partnership to drive value or primarily as an equity method investment, and if there are current supplier arrangements.

A: Brian Tyler clarified that the transaction has not closed, so there are no current interfaces, but they view the investment as incubating future growth platforms adjacent to their core strategy, with CD&R managing day-to-day operations.